6 in 1 Covid-19, Influenza A + B, RSV, Adenovirus & Mycoplasma pneumoniae

6 in 1 Covid-19, Influenza A + B, RSV, Adenovirus & Mycoplasma pneumoniae

The SARS-CoV-2/Influenza A+B/RSV/Adenovirus/M.pneumoniae Antigen Combo Rapid Test (Nasopharyngeal Swab) is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Nucleocapsid protein, Influenza A, Influenza B, Respiratory Syncytial Virus(RSV), Adenovirus and M.pneumoniae antigens in nasopharyngeal swab specimens from individuals with suspected SARS-CoV-2/Influenza/RSV/Adenovirus/M.pneumoniae infection in conjunction with clinical presentation and the results of other laboratory tests.
Results are for the detection of SARS-CoV-2, Influenza A+B, RSV, Adenovirus and M.pneumoniae antigens. An antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of correlative antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out other bacterial/viral infection. The agent detected may not be the definite cause of disease.
Negative results do not preclude SARS-CoV-2/Influenza A+B/RSV/Adenovirus/M.pneumoniae infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with SARS-CoV-2, Influenza A+B, RSV , Adenovirus and M.pneumoniae